Assessing the assessment

A scoping review of the mode of patient-reported outcome assessment in solid cancer clinical trials

Dados Bibliográficos

ID15296221
AutoresN J Hubel (0009-0003-5501-1583, Innsbruck Medical University), Niclas Hubel, Daniela Krepper (0009-0009-0026-9548, Innsbruck Medical University), Lotte van der Weijst (0000-0001-8658-1894, European Organisation for Research and Treatment of Cancer), Abigirl Machingura (0000-0003-0289-9614, European Organisation for Research and Treatment of Cancer), Claudia Seidl (Innsbruck Medical University), Samuel Vorbach (0009-0003-1711-1604, Innsbruck Medical University), Samuel M Vorbach, Michelle Veil (Innsbruck Medical University), Johannes M Giesinger (0000-0003-2744-5950, Innsbruck Medical University), Monika Sztankay (0000-0002-7938-1250, Innsbruck Medical University), Scottie Kern (Critical Path Institute), Deborah Fitzsimmons (0000-0002-7286-8410, Swansea University), Dagmara Kuliś (0000-0002-2289-2113, European Organisation for Research and Treatment of Cancer), Madeline Pe (0009-0005-2531-0050, European Organisation for Research and Treatment of Cancer), Bernhard Holzner (0000-0002-3389-3621, Innsbruck Medical University), Jens Lehmann (0000-0001-6580-6644, Innsbruck Medical University, autor correspondente)
Ano2026
Volume35
Fascículo4
Data de publicação2026-03-01
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoQuality of Life Research (JOURNAL)
Identificadores do periódicoISSN: 0962-9343 • E-ISSN: 1573-2649
EditoraSpringer Science+Business Media (PUBLISHER • DE)
DOI10.1007/s11136-026-04179-y
PMID41764668
OpenAlexW7133129314
IdiomaEN
Referências citadas36

Despite clear guidelines, reporting of the mode of PRO assessment remains inadequate, and active review of PRO data is uncommon. Strengthening transparency and using PROs more actively within trials could enhance patient-centered cancer research

Cancer · Clinical trial · MEDLINE · Outcome (game theory · Public health · Quality of life (healthcare · Quality of Life Research · Transparency (behavior · Cancer survivorship and care · Cancer Treatment and Pharmacology · Economic and Financial Impacts of Cancer